Skip to main content
Premium Trial:

Request an Annual Quote

Cancer Genetics' Cervical Cancer Test Receives CE Mark

NEW YORK (GenomeWeb) – Cancer Genetics has received CE marking for its DNA probe-based in vitro diagnostic cervical cancer screening test, the company said today.

The CE mark, which shows a product is in compliance with European Union safety laws, will enable the company to market the FISH-based HPV-associated Cancer Test (FHACT) freely in the European Economic Area, which includes the EU member states and the European Free Trade Association, or 31 nations in all.

The FHACT test uses DNA-FISH probes to identify women who are most at risk for cervical disease by screening for genomic changes related to cancer progression. The test can be used on leftover prep specimens and convention Pap smears.

In addition to identifying women at highest risk for cervical disease, the test also can reduce unnecessary and invasive testing and over-treatment among women who are at a lower risk for disease progression, the Rutherford, NJ-based company said.

"Cervical cancer screening is evolving, but there remains a need for more definitive and genomically informed diagnosis," Cancer Genetics CEO Panna Sharma said in a statement.

Having the CE mark will enable the company to expand its FHACT sales in Europe and allow wider global adoption, said he added.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.